JP2022504596A5 - - Google Patents

Info

Publication number
JP2022504596A5
JP2022504596A5 JP2021519698A JP2021519698A JP2022504596A5 JP 2022504596 A5 JP2022504596 A5 JP 2022504596A5 JP 2021519698 A JP2021519698 A JP 2021519698A JP 2021519698 A JP2021519698 A JP 2021519698A JP 2022504596 A5 JP2022504596 A5 JP 2022504596A5
Authority
JP
Japan
Prior art keywords
sequence
γglu
ntstc
isolated polypeptide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504596A (ja
JP7636321B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055696 external-priority patent/WO2020077129A1/en
Publication of JP2022504596A publication Critical patent/JP2022504596A/ja
Publication of JP2022504596A5 publication Critical patent/JP2022504596A5/ja
Priority to JP2024155106A priority Critical patent/JP2025000663A/ja
Application granted granted Critical
Publication of JP7636321B2 publication Critical patent/JP7636321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519698A 2018-10-11 2019-10-10 ヒトアミリンアナログペプチド及び使用方法 Active JP7636321B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024155106A JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11
US62/744,236 2018-10-11
PCT/US2019/055696 WO2020077129A1 (en) 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024155106A Division JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Publications (3)

Publication Number Publication Date
JP2022504596A JP2022504596A (ja) 2022-01-13
JP2022504596A5 true JP2022504596A5 (cg-RX-API-DMAC7.html) 2022-10-19
JP7636321B2 JP7636321B2 (ja) 2025-02-26

Family

ID=68393080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519698A Active JP7636321B2 (ja) 2018-10-11 2019-10-10 ヒトアミリンアナログペプチド及び使用方法
JP2024155106A Pending JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024155106A Pending JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Country Status (13)

Country Link
US (3) US12018059B2 (cg-RX-API-DMAC7.html)
EP (1) EP3864031A1 (cg-RX-API-DMAC7.html)
JP (2) JP7636321B2 (cg-RX-API-DMAC7.html)
KR (1) KR102911883B1 (cg-RX-API-DMAC7.html)
CN (2) CN113195524A (cg-RX-API-DMAC7.html)
AR (1) AR116632A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019357621B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006823A2 (cg-RX-API-DMAC7.html)
IL (2) IL320142A (cg-RX-API-DMAC7.html)
MX (1) MX2021004185A (cg-RX-API-DMAC7.html)
SG (1) SG11202103586UA (cg-RX-API-DMAC7.html)
TW (1) TW202028228A (cg-RX-API-DMAC7.html)
WO (1) WO2020077129A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115968376A (zh) * 2020-04-17 2023-04-14 I2O治疗公司 长效胰高血糖素受体选择性肽和使用方法
US20230158116A1 (en) * 2020-04-20 2023-05-25 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
KR20230073176A (ko) * 2020-09-24 2023-05-25 구브라 에이피에스 개선된 아밀린 수용체(hAMY3R) 효능을 갖는 HAM15-52 유사체
SMT202600248T1 (it) * 2020-12-16 2026-07-16 Medimmune Ltd Polipeptidi e usi di essi
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
CN113880935B (zh) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
EP1288224B1 (en) 1993-08-09 2008-06-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutic peptide derivatives
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
DE69720190T2 (de) 1996-02-02 2003-12-11 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
CA2315890C (en) 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
EP1041968B1 (en) 1997-12-29 2004-03-03 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
ATE342051T1 (de) 1997-12-30 2006-11-15 Alza Corp Verabreichungssystem für wirkstoffe mit einem membranstöpsel
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
DE69906132T2 (de) 1998-12-31 2003-12-18 Alza Corp., Mountain View Osmotisches verabreichungsystem mit raumsparenden kolben
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
AU2001263230B2 (en) 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
DE60137876D1 (de) 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性glp−1製剤
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
AU2003278929A1 (en) 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010046357A1 (en) * 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
ES2622877T3 (es) 2009-01-22 2017-07-07 Keybioscience Ag Tratamiento para la obesidad
EP2405934B1 (en) 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
RU2603093C2 (ru) 2010-04-15 2016-11-20 Дженентек, Инк. Антитела против полиубиквитина и способы их применения
WO2012162547A2 (en) * 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
EP2718315B1 (en) 2011-06-10 2017-12-27 Novo Nordisk A/S Pramlintide derivatives
PL2838914T3 (pl) 2012-04-19 2017-11-30 Novo Nordisk A/S Analogi ludzkiej amyliny
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina

Similar Documents

Publication Publication Date Title
AU677792B2 (en) New aminoacid derivates, process for producing the same and pharmaceutical compositions containing these compounds
JP3266311B2 (ja) 新規ポリペプチドおよびこれを用いる抗hiv剤
JP6334399B2 (ja) 自己組織化ペプチド誘導体の製造方法
CN113816990B (zh) 修饰的氨基酸及其在adc中的应用
HRP950276A2 (en) New amino acid derivatives, process for their preparation and pharmaceutical compounds (ii) containing such compounds
JP2025039570A (ja) ペプチド及びペプチド関連化合物の高浸透性プロドラッグ組成物
DK150146B (da) Analogifremgangsmaade til fremstilling af somatostatinanaloge hepta- eller octapeptider eller salte eller complexer deraf
MXPA96005128A (en) New derivatives of amino acids, procedures for their preparation and pharmaceutical compositions that contain these compounds
AU2016353547B2 (en) Cyclic peptides targeting α4β7 integrin
NZ503061A (en) Cyclic tetrapeptide derivatives and use as anti-cancer agents
CN105683156A (zh) 含有肽修饰剂的氨基二酸
CN102036676A (zh) 新颖的双重靶向性抗肿瘤轭合物
US11168114B2 (en) Process for the manufacture of degarelix and its intermediates
JPWO1992004374A1 (ja) 新規ポリペプチドおよびこれを用いる抗hiv剤
JPH06504055A (ja) ヘキサーおよびヘプタペプチドのアナフィラトキシン受容体リガンド
JP2024502740A5 (cg-RX-API-DMAC7.html)
JPS59170051A (ja) 薬理活性を有するトリペプチド誘導体
JPH0341091A (ja) 酵素阻害性ペプチド誘導体
CN106279357A (zh) 双[(乙酰-Lys(AA)-OBzl)吲哚]乙烷,其制备,活性和应用
TW434261B (en) Motilin-like polypeptides with gastrointestinal motor stimulating activity
ES2275460T3 (es) Dipeptidos que contienen ciclopentano-beta-aminoacidos.
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
JP2014501750A5 (cg-RX-API-DMAC7.html)
JP3939354B2 (ja) 抗腫瘍性ペプチド
JPS63218697A (ja) ジフルオルシクロスタチン含有ポリペプチド